Page last updated: 2024-11-01

nomifensine and Parkinsonian Disorders

nomifensine has been researched along with Parkinsonian Disorders in 1 studies

Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research Excerpts

ExcerptRelevanceReference
" The nicotinic agonists were given acutely and repeatedly either alone or in combination with a dopamine uptake inhibitor, nomifensine."1.33Comparison of the effects of nicotine and epibatidine given in combination with nomifensine on rotational behaviour in rats. ( Ahtee, L; Janhunen, S; Tuominen, RK, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Janhunen, S1
Tuominen, RK1
Ahtee, L1

Other Studies

1 other study available for nomifensine and Parkinsonian Disorders

ArticleYear
Comparison of the effects of nicotine and epibatidine given in combination with nomifensine on rotational behaviour in rats.
    Neuroscience letters, 2005, Jun-24, Volume: 381, Issue:3

    Topics: Adrenergic Agents; Animals; Brain; Bridged Bicyclo Compounds, Heterocyclic; Dopamine Uptake Inhibito

2005